Osteopontin and disease activity in patients with recent-onset systemic lupus erythematosus: results from the SLICC Inception Cohort

Lina Wirestam; Helena Enocsson; Thomas Skogh; Leonid Padyukov; Andreas Jönsen; Murray B. Urowitz; Dafna D. Gladman; Juanita Romero-diaz; Sang-cheol Bae; Paul R. Fortin; Jorge Sanchez-guerrero; Ann E. Clarke; Sasha Bernatsky; Caroline Gordon; John G. Hanly; Daniel Wallace; David A. Isenberg; Anisur Rahman; Joan Merrill; Ellen Ginzler; Graciela S. Alarcón; W. Winn Chatham; Michelle Petri; Munther Khamashta; Cynthia Aranow; Meggan Mackay; Mary Anne Dooley; Susan Manzi; Rosalind Ramsey-goldman; Ola Nived; Kristjan Steinsson; Asad Zoma; Guillermo Ruiz-irastorza; Sam Lim; Ken Kalunian; Murat Inanc; Ronald Van Vollenhoven; Manuel Ramos-casals; Diane L. Kamen; Søren Jacobsen; Christine Peschken; Anca Askanase; Thomas Stoll; Ian N. Bruce; Jonas Wetterö; Christopher Sjöwall

doi:10.3899/jrheum.180713

Osteopontin and disease activity in patients with recent-onset systemic lupus erythematosus: results from the SLICC Inception Cohort

Lina Wirestam, Helena Enocsson, Thomas Skogh, Leonid Padyukov, Andreas Jönsen, Murray B. Urowitz, Dafna D. Gladman, Juanita Romero-diaz, Sang-cheol Bae, Paul R. Fortin, Jorge Sanchez-guerrero, Ann E. Clarke, Sasha Bernatsky, Caroline Gordon, John G. Hanly, Daniel Wallace, David A. Isenberg, Anisur Rahman, Joan Merrill, Ellen GinzlerGraciela S. Alarcón, W. Winn Chatham, Michelle Petri, Munther Khamashta, Cynthia Aranow, Meggan Mackay, Mary Anne Dooley, Susan Manzi, Rosalind Ramsey-goldman, Ola Nived, Kristjan Steinsson, Asad Zoma, Guillermo Ruiz-irastorza, Sam Lim, Ken Kalunian, Murat Inanc, Ronald Van Vollenhoven, Manuel Ramos-casals, Diane L. Kamen, Søren Jacobsen, Christine Peschken, Anca Askanase, Thomas Stoll, Ian N. Bruce, Jonas Wetterö, Christopher Sjöwall

Inflammation and Ageing

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

97 Downloads (Pure)

Abstract

Objective: In cross-sectional studies, elevated osteopontin (OPN) levels have been proposed to reflect, and/or precede, progressive organ damage and disease severity in systemic lupus erythematosus (SLE). We aimed, in a cohort of recent-onset SLE, to determine whether raised serum OPN levels precede damage and/or associate with disease activity or certain disease phenotypes.

Methods: We included 344 patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort who had 5-years of follow-up data available. All patients fulfilled the 1997 American College of Rheumatology (ACR) criteria. Baseline sera from patients and from age- and sex-matched population-based controls were analysed for OPN using ELISA. Disease activity and damage were assessed at each annual follow-up visit using the SLE Disease Activity Index 2000 (SLEDAI-2K) and the SLICC/ACR damage index (SDI), respectively.

Results: Compared to controls, baseline OPN was raised fourfold in SLE cases (p<0.0001). After relevant adjustments in a binary logistic regression model, OPN levels failed to significantly predict global damage accrual defined as SDI≥1 at 5 years. However, baseline OPN correlated with SLEDAI-2K at enrolment into the cohort (r=0.27, p<0.0001), and patients with high disease activity (SLEDAI-2K≥5) had raised serum OPN (p<0.0001). In addition, higher OPN levels were found in patients with persistent disease activity (p=0.0006), in cases with renal involvement (p<0.0001) and impaired estimated glomerular filtration rate (p=0.01).

Conclusion: The performance of OPN to predict development of organ damage was not impressive. However, OPN associated significantly with lupus nephritis and with raised disease activity at enrolment, as well as over time.

Original language	English
Article number	180713
Pages (from-to)	492-500
Number of pages	9
Journal	The Journal of Rheumatology
Volume	46
Issue number	5
DOIs	https://doi.org/10.3899/jrheum.180713
Publication status	Published - 1 Jan 2019

Keywords

Systemic Lupus Erythematosus
Biomarkers
Osteopontin
Disease Activity
Organ Damage
Prognosis

Access to Document

10.3899/jrheum.180713Licence: None: All rights reserved

Osteopontin_and_Disease_Activity_in_Patients_with_Recent_onset_Systemic_Lupus_Erythematosus_Lina_Wirestam_et_al_The_Journal_of_Rheumatology_2018_
Checked for eligibility: 27/09/2018 This is a pre-copyediting, author-produced PDF of an article accepted for publication in The Journal of Rheumatology following peer review. The definitive publisher-authenticated version Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort, Lina Wirestam et al, The Journal of Rheumatology Jan 2019, jrheum.180713; DOI: 10.3899/jrheum.180713 is available online at: http://www.jrheum.org/content/early/2019/01/11/jrheum.180713.
Accepted author manuscript, 244 KBLicence: None: All rights reserved

http://www.jrheum.org/lookup/doi/10.3899/jrheum.180713Licence: None: All rights reserved

Cite this

Wirestam, L., Enocsson, H., Skogh, T., Padyukov, L., Jönsen, A., Urowitz, M. B., Gladman, D. D., Romero-diaz, J., Bae, S., Fortin, P. R., Sanchez-guerrero, J., Clarke, A. E., Bernatsky, S., Gordon, C., Hanly, J. G., Wallace, D., Isenberg, D. A., Rahman, A., Merrill, J., ... Sjöwall, C. (2019). Osteopontin and disease activity in patients with recent-onset systemic lupus erythematosus: results from the SLICC Inception Cohort. The Journal of Rheumatology, 46(5), 492-500. Article 180713. https://doi.org/10.3899/jrheum.180713

@article{0363618a06b84ec7a711632ee5cf5042,

title = "Osteopontin and disease activity in patients with recent-onset systemic lupus erythematosus: results from the SLICC Inception Cohort",

abstract = "Objective: In cross-sectional studies, elevated osteopontin (OPN) levels have been proposed to reflect, and/or precede, progressive organ damage and disease severity in systemic lupus erythematosus (SLE). We aimed, in a cohort of recent-onset SLE, to determine whether raised serum OPN levels precede damage and/or associate with disease activity or certain disease phenotypes.Methods: We included 344 patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort who had 5-years of follow-up data available. All patients fulfilled the 1997 American College of Rheumatology (ACR) criteria. Baseline sera from patients and from age- and sex-matched population-based controls were analysed for OPN using ELISA. Disease activity and damage were assessed at each annual follow-up visit using the SLE Disease Activity Index 2000 (SLEDAI-2K) and the SLICC/ACR damage index (SDI), respectively. Results: Compared to controls, baseline OPN was raised fourfold in SLE cases (p<0.0001). After relevant adjustments in a binary logistic regression model, OPN levels failed to significantly predict global damage accrual defined as SDI≥1 at 5 years. However, baseline OPN correlated with SLEDAI-2K at enrolment into the cohort (r=0.27, p<0.0001), and patients with high disease activity (SLEDAI-2K≥5) had raised serum OPN (p<0.0001). In addition, higher OPN levels were found in patients with persistent disease activity (p=0.0006), in cases with renal involvement (p<0.0001) and impaired estimated glomerular filtration rate (p=0.01). Conclusion: The performance of OPN to predict development of organ damage was not impressive. However, OPN associated significantly with lupus nephritis and with raised disease activity at enrolment, as well as over time. ",

keywords = "Systemic Lupus Erythematosus, Biomarkers, Osteopontin, Disease Activity, Organ Damage, Prognosis",

author = "Lina Wirestam and Helena Enocsson and Thomas Skogh and Leonid Padyukov and Andreas J{\"o}nsen and Urowitz, {Murray B.} and Gladman, {Dafna D.} and Juanita Romero-diaz and Sang-cheol Bae and Fortin, {Paul R.} and Jorge Sanchez-guerrero and Clarke, {Ann E.} and Sasha Bernatsky and Caroline Gordon and Hanly, {John G.} and Daniel Wallace and Isenberg, {David A.} and Anisur Rahman and Joan Merrill and Ellen Ginzler and Alarc{\'o}n, {Graciela S.} and Chatham, {W. Winn} and Michelle Petri and Munther Khamashta and Cynthia Aranow and Meggan Mackay and Dooley, {Mary Anne} and Susan Manzi and Rosalind Ramsey-goldman and Ola Nived and Kristjan Steinsson and Asad Zoma and Guillermo Ruiz-irastorza and Sam Lim and Ken Kalunian and Murat Inanc and Vollenhoven, {Ronald Van} and Manuel Ramos-casals and Kamen, {Diane L.} and S{\o}ren Jacobsen and Christine Peschken and Anca Askanase and Thomas Stoll and Bruce, {Ian N.} and Jonas Wetter{\"o} and Christopher Sj{\"o}wall",

year = "2019",

month = jan,

day = "1",

doi = "10.3899/jrheum.180713",

language = "English",

volume = "46",

pages = "492--500",

journal = "The Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "5",

}

Wirestam, L, Enocsson, H, Skogh, T, Padyukov, L, Jönsen, A, Urowitz, MB, Gladman, DD, Romero-diaz, J, Bae, S, Fortin, PR, Sanchez-guerrero, J, Clarke, AE, Bernatsky, S, Gordon, C, Hanly, JG, Wallace, D, Isenberg, DA, Rahman, A, Merrill, J, Ginzler, E, Alarcón, GS, Chatham, WW, Petri, M, Khamashta, M, Aranow, C, Mackay, M, Dooley, MA, Manzi, S, Ramsey-goldman, R, Nived, O, Steinsson, K, Zoma, A, Ruiz-irastorza, G, Lim, S, Kalunian, K, Inanc, M, Vollenhoven, RV, Ramos-casals, M, Kamen, DL, Jacobsen, S, Peschken, C, Askanase, A, Stoll, T, Bruce, IN, Wetterö, J & Sjöwall, C 2019, 'Osteopontin and disease activity in patients with recent-onset systemic lupus erythematosus: results from the SLICC Inception Cohort', The Journal of Rheumatology, vol. 46, no. 5, 180713, pp. 492-500. https://doi.org/10.3899/jrheum.180713

TY - JOUR

T1 - Osteopontin and disease activity in patients with recent-onset systemic lupus erythematosus

T2 - results from the SLICC Inception Cohort

AU - Wirestam, Lina

AU - Enocsson, Helena

AU - Skogh, Thomas

AU - Padyukov, Leonid

AU - Jönsen, Andreas

AU - Urowitz, Murray B.

AU - Gladman, Dafna D.

AU - Romero-diaz, Juanita

AU - Bae, Sang-cheol

AU - Fortin, Paul R.

AU - Sanchez-guerrero, Jorge

AU - Clarke, Ann E.

AU - Bernatsky, Sasha

AU - Gordon, Caroline

AU - Hanly, John G.

AU - Wallace, Daniel

AU - Isenberg, David A.

AU - Rahman, Anisur

AU - Merrill, Joan

AU - Ginzler, Ellen

AU - Alarcón, Graciela S.

AU - Chatham, W. Winn

AU - Petri, Michelle

AU - Khamashta, Munther

AU - Aranow, Cynthia

AU - Mackay, Meggan

AU - Dooley, Mary Anne

AU - Manzi, Susan

AU - Ramsey-goldman, Rosalind

AU - Nived, Ola

AU - Steinsson, Kristjan

AU - Zoma, Asad

AU - Ruiz-irastorza, Guillermo

AU - Lim, Sam

AU - Kalunian, Ken

AU - Inanc, Murat

AU - Vollenhoven, Ronald Van

AU - Ramos-casals, Manuel

AU - Kamen, Diane L.

AU - Jacobsen, Søren

AU - Peschken, Christine

AU - Askanase, Anca

AU - Stoll, Thomas

AU - Bruce, Ian N.

AU - Wetterö, Jonas

AU - Sjöwall, Christopher

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: In cross-sectional studies, elevated osteopontin (OPN) levels have been proposed to reflect, and/or precede, progressive organ damage and disease severity in systemic lupus erythematosus (SLE). We aimed, in a cohort of recent-onset SLE, to determine whether raised serum OPN levels precede damage and/or associate with disease activity or certain disease phenotypes.Methods: We included 344 patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort who had 5-years of follow-up data available. All patients fulfilled the 1997 American College of Rheumatology (ACR) criteria. Baseline sera from patients and from age- and sex-matched population-based controls were analysed for OPN using ELISA. Disease activity and damage were assessed at each annual follow-up visit using the SLE Disease Activity Index 2000 (SLEDAI-2K) and the SLICC/ACR damage index (SDI), respectively. Results: Compared to controls, baseline OPN was raised fourfold in SLE cases (p<0.0001). After relevant adjustments in a binary logistic regression model, OPN levels failed to significantly predict global damage accrual defined as SDI≥1 at 5 years. However, baseline OPN correlated with SLEDAI-2K at enrolment into the cohort (r=0.27, p<0.0001), and patients with high disease activity (SLEDAI-2K≥5) had raised serum OPN (p<0.0001). In addition, higher OPN levels were found in patients with persistent disease activity (p=0.0006), in cases with renal involvement (p<0.0001) and impaired estimated glomerular filtration rate (p=0.01). Conclusion: The performance of OPN to predict development of organ damage was not impressive. However, OPN associated significantly with lupus nephritis and with raised disease activity at enrolment, as well as over time.

AB - Objective: In cross-sectional studies, elevated osteopontin (OPN) levels have been proposed to reflect, and/or precede, progressive organ damage and disease severity in systemic lupus erythematosus (SLE). We aimed, in a cohort of recent-onset SLE, to determine whether raised serum OPN levels precede damage and/or associate with disease activity or certain disease phenotypes.Methods: We included 344 patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort who had 5-years of follow-up data available. All patients fulfilled the 1997 American College of Rheumatology (ACR) criteria. Baseline sera from patients and from age- and sex-matched population-based controls were analysed for OPN using ELISA. Disease activity and damage were assessed at each annual follow-up visit using the SLE Disease Activity Index 2000 (SLEDAI-2K) and the SLICC/ACR damage index (SDI), respectively. Results: Compared to controls, baseline OPN was raised fourfold in SLE cases (p<0.0001). After relevant adjustments in a binary logistic regression model, OPN levels failed to significantly predict global damage accrual defined as SDI≥1 at 5 years. However, baseline OPN correlated with SLEDAI-2K at enrolment into the cohort (r=0.27, p<0.0001), and patients with high disease activity (SLEDAI-2K≥5) had raised serum OPN (p<0.0001). In addition, higher OPN levels were found in patients with persistent disease activity (p=0.0006), in cases with renal involvement (p<0.0001) and impaired estimated glomerular filtration rate (p=0.01). Conclusion: The performance of OPN to predict development of organ damage was not impressive. However, OPN associated significantly with lupus nephritis and with raised disease activity at enrolment, as well as over time.

KW - Systemic Lupus Erythematosus

KW - Biomarkers

KW - Osteopontin

KW - Disease Activity

KW - Organ Damage

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=85065255644&partnerID=8YFLogxK

U2 - 10.3899/jrheum.180713

DO - 10.3899/jrheum.180713

M3 - Article

SN - 0315-162X

VL - 46

SP - 492

EP - 500

JO - The Journal of Rheumatology

JF - The Journal of Rheumatology

IS - 5

M1 - 180713

ER -

Osteopontin and disease activity in patients with recent-onset systemic lupus erythematosus: results from the SLICC Inception Cohort

Abstract

Keywords

Access to Document

Fingerprint

Cite this